The estimated Net Worth of Samuel R Saks is at least $2.85 Milion dollars as of 21 June 2016. Mr. Saks owns over 25,000 units of Protagonist Therapeutics Inc stock worth over $2,846,405 and over the last 17 years he sold PTGX stock worth over $0. In addition, he makes $0 as Chief Medical Officer at Protagonist Therapeutics Inc.
Sign up
Mr. Saks PTGX stock SEC Form 4 insiders trading
Samuel has made over 6 trades of the Protagonist Therapeutics Inc stock since 2007, according to the Form 4 filled with the SEC. Most recently he bought 25,000 units of PTGX stock worth $50,000 on 21 June 2016.
The largest trade he's ever made was buying 25,000 units of Protagonist Therapeutics Inc stock on 21 June 2016 worth over $50,000. On average, Samuel trades about 2,521 units every 87 days since 2007. As of 21 June 2016 he still owns at least 63,550 units of Protagonist Therapeutics Inc stock.
You can see the complete history of Mr. Saks stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Samuel Saks biography
Samuel Saks M.D. serves as Chief Medical Officer of the Company. He has served as the Company's Chief Medical Officer since May 2019, and served as the Company's Chief Development Officer from May 2018 to May 2019. Prior to joining Protagonist, he served as Chief Development Officer and board member at Auspex Pharmaceuticals, a biopharmaceutical company, from December 2010 until the time of its acquisition by Teva Pharmaceuticals in May 2015. Before his tenure at Auspex, Dr. Saks was a co-founder of Jazz Pharmaceuticals where he also previously served as Chief Executive Officer of Jazz from March 2003 to March 2009. Earlier in his career, he held positions as company group chairman of ALZA Corporation and as a member of the Johnson & Johnson Pharmaceutical Operating Committee. Dr. Saks has also held leadership and management positions at Schering-Plough, XOMA Corporation and Genentech. He previously served as a director of PDL BioPharma, a public company, until August 2019, as a director of Tonix Pharmaceutical Holding Company, a public company, from May 2012 until August 2018 and as a director of Depomed Inc. (now Assertio Therapeutics), a public company, from October 2012 until March 2017. Dr. Saks also serves as a director of two privately held companies. Dr. Saks received a B.S. in Biology and his M.D. from the University of Illinois.
How old is Samuel Saks?
Samuel Saks is 65, he's been the Chief Medical Officer of Protagonist Therapeutics Inc since 2019. There are 4 older and 15 younger executives at Protagonist Therapeutics Inc. The oldest executive at Protagonist Therapeutics Inc is Dr. David Y. Liu, 71, who is the Chief Scientific Officer and Head of Discovery & Pre-Clinical Devel..
What's Samuel Saks's mailing address?
Samuel's mailing address filed with the SEC is C/O PROTAGONIST THERAPEUTICS, INC., 7707 GATEWAY BLVD., SUITE 140, NEWARK, CA, 94560.
Insiders trading at Protagonist Therapeutics Inc
Over the last 8 years, insiders at Protagonist Therapeutics Inc have traded over $11,629,969 worth of Protagonist Therapeutics Inc stock and bought 3,007,840 units worth $35,519,073 . The most active insiders traders include Capital Partners Gp, L.L.C...., & Johnson Johnson & Johnson... a X L.P.Canaan Partners X Llc.... On average, Protagonist Therapeutics Inc executives and independent directors trade stock every 37 days with the average trade being worth of $2,387,307. The most recent stock trade was executed by William D. Waddill on 24 July 2024, trading 8,000 units of PTGX stock currently worth $103,040.
What does Protagonist Therapeutics Inc do?
protagonist therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform which is utilized to discover and develop novel peptide-based drugs to address significant unmet medical needs. its primary focus is on developing potential first-in-class oral targeted therapy-based peptide drugs that work by blocking biological pathways that are currently targeted by marketed injectable antibody drugs. protagonist's initial lead peptide product candidates, ptg-100 and ptg-200, are based on this approach, and the company believes these candidates have the potential to transform the existing treatment paradigm for inflammatory bowel disease (ibd), consisting primarily of ulcerative colitis and crohn's disease. ptg-100, a potential first-in-class oral peptide alpha-4-beta-7 integrin antagonist, is currently in a global phase 2b clinical trial for treatment of moderate-to-severe ulcerative colitis. ptg-200, a first-in-class oral interleukin-23 receptor antagonist
What does Protagonist Therapeutics Inc's logo look like?
Complete history of Mr. Saks stock trades at Jazz Pharmaceuticals plc, PDL Biopharma Inc, Protagonist Therapeutics Inc a Tonix Pharmaceuticals Corp
Protagonist Therapeutics Inc executives and stock owners
Protagonist Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Dinesh Patel,
President, Chief Executive Officer, Director -
Suneel Gupta,
Chief Development Officer -
David Liu,
Chief Scientific Officer, Head of Research & Development -
Dr. Dinesh V. Patel Ph.D.,
CEO, Pres, Interim PAO, Sec. & Director -
Dr. David Y. Liu,
Chief Scientific Officer and Head of Discovery & Pre-Clinical Devel. -
Dr. Suneel K. Gupta Ph.D.,
Chief Devel. Officer -
Harold Selick,
Independent Chairman of the Board -
William Waddill,
Independent Director -
Bryan Giraudo,
Independent Director -
Sarah Noonberg,
Independent Director -
Lewis Williams,
Independent Director -
Sarah O'Dowd,
Independent Director -
Brian Korb,
IR Contact Officer -
Samuel Saks,
Chief Medical Officer -
Donald Kalkofen,
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer -
Asif Ali,
Exec. VP & Chief Financial Officer -
Dr. Scott Eric Plevy M.D.,
Exec. VP and Therapeutic Head of Gastroenterology -
Dr. Ashok Bhandari Ph.D.,
Sr. VP of Discovery Chemistry & Process Research -
Mohammad Masjedizadeh,
Exec. VP & CTO -
Donald A. Kalkofen,
Chief Financial Officer -
Dr. Larry Mattheakis,
Sr. VP of Discovery Biology & Translational Research -
Dr. Ashok Bhandari,
Sr. VP of Discovery Chemistry & Process Research -
Carena Spivey,
Exec. Director of HR -
Matthew M. Gosling,
Exec. VP & Gen. Counsel -
Dr. Mark Smythe,
Founder & VP Technology -
Dr. Richard S. Shames,
Clinical Advisor -
Arturo Md Molina,
Chief Medical Officer -
Armen Shanafelt,
Director -
Chaitan Phd Khosla,
Director -
Julie Papanek,
Director -
Richard S. Shames,
Chief Medical Officer -
Thomas P. O'neil,
Chief Financial Officer -
William A Hodder,
Sr. VP - Corporate Development -
& Johnson Johnson & Johnson...,
-
X L.P.Canaan Partners X Llc...,
-
Management Group, Llc Lilly...,
-
Asif Ali,
Chief Financial Officer -
Capital Partners Gp, L.L.C....,
-
Daniel N Jr Swisher,
Director